Inotuzumab ozogamicin (CMC-544) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesNCT01664910I/IIM.D. Anderson Cancer Center / Pfizer
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaNCT00868608IIPfizer / UCB Pharma
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)NCT02311998I/IIM.D. Anderson Cancer Center / Pfizer
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin’s LymphomaNCT01055496IPfizer / UCB Pharma
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin’s LymphomaNCT00867087IIPfizer / UCB Pharma
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin’s Lymphoma (NHL)NCT00299494I/IIPfizer / UCB Pharma
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaNCT01925131ISouthwest Oncology Group / National Cancer Institute (NCI)
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaNCT01363297I/IIPfizer / UCB Pharma
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)NCT01134575IM.D. Anderson Cancer Center / Pfizer (Wyeth)
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyNCT01232556IIIPfizer / UCB Pharma
Study Evaluating CMC-544 In B-Cell Non-Hodgkin’s LymphomaNCT00073749IPfizer
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator’s Choice In Follicular Non-Hodgkin’s Lymphoma (NHL)NCT00562965IIIPfizer
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseNCT01562990I/IIThe Lymphoma Academic Research Organisation / Pfizer
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabNCT00724971IPfizer
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphomaNCT01535989ICristiana Sessa, Oncology Institute of Southern Switzerland
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin’s Lymphoma (NHL)NCT00717925IPfizer / Wyeth
A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaNCT01564784IIIPfizer / UCB Pharma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing ChemotherapyNCT01679119IIUniversity College, London / Pfizer / Cancer Research UK
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)NCT01371630I/IIM.D. Anderson Cancer Center

More information: Inotuzumab ozogamicin (CMC-544) Drug Description